



Dedicated To Life

June 15, 2024

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Sub.: Zydus receives OAI from the USFDA for its injectable manufacturing facility at Ahmedabad

Dear Sir / Madam,

We wish to inform that the company has received the report from the USFDA for the inspection conducted at the injectables manufacturing facility of Zydus Lifesciences, FEI 3007621329, from 18th March to 27th March 2024 located at Pharmez Special Economic Zone, Matoda, Gujarat, India.

The USFDA has determined that the inspection classification of this facility is "Official Action Indicated" (OAI). Furthermore, the regulatory agency has granted a teleconference Regulatory Meeting to discuss all the implemented and proposed actions. The company will work closely with the agency to resolve this regulatory status of this facility expeditiously.

This may kindly be considered as a disclosure pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI

COMPANY SECRETARY

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

